Pharmaceutical company Novo Nordisk A/S (ADR) (NYSE:NVO) is one of those companies which prove that being less diversified can be good too.

Novo Nordisk A/S (NVO, NOVO-B.KO), the world's top maker of insulin, said its hotly anticipated Tresiba drug may not hit the U.S.

Novo Nordisk A/S (ADR) (NYSE:NVO) wants to expand the earnings potential of its bestselling diabetes drug Victoza. The drug already has FDA permission to note the potential for weight loss on Victoza's label.

Zacks' analyst wrote, �Novo Nordisk posted first quarter 2013 earnings of $1.94 per ADR, up 32.5% from the year-ago period.

Novo Nordisk (NYSE: NVO)'s stock had its �neutral� rating restated by Zacks in a research report issued to clients and investors on Monday, Analyst Ratings Network reports.